Virpax Enterprise Value from 2010 to 2024

VRPX Stock

USD 0.47 0.10 17.54%

Virpax Pharmaceuticals Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value is likely to outpace its year average in 2024. Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. View All Fundamentals

Enterprise Value

First Reported

2010-12-31

Previous Quarter

-5.4 M

Current Value

-5.1 M

Quarterly Volatility

160.2 M

Credit Downgrade

Yuan Drop

Covid

Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 988 or Interest Expense of 126.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.03. Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Virpax Pharmaceuticals Correlation against competitors.

For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.

Latest Virpax Pharmaceuticals' Enterprise Value Growth Pattern

Below is the plot of the Enterprise Value of Virpax Pharmaceuticals over the last few years. Enterprise Value (or EV) is usually referred to as Virpax Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Virpax Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Virpax Pharmaceuticals value than its market capitalization because it takes into account all of Virpax Pharmaceuticals existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Virpax Pharmaceuticals' Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virpax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 4.57 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Enterprise Value

Timeline

Virpax Enterprise Value Regression Statistics

	Arithmetic Mean	197,368,260
	Coefficient Of Variation	81.18
	Mean Deviation	151,202,233
	Median	323,370,121
	Standard Deviation	160,221,152
	Sample Variance	25670.8T
	Range	335.1M
	R-Value	(0.86)
	Mean Square Error	6983T
	R-Squared	0.75
	Significance	0.000032
	Slope	(30,973,034)
	Total Sum of Squares	359391.4T

Virpax Enterprise Value History

	2024	-5.1 M
	2023	-5.4 M
	2022	-11.7 M
	2021	3.3 M
	2020	33.8 M
	2019	35.3 M

Other Fundumenentals of Virpax Pharmaceuticals

	Enterprise Value Over E B I T D A
	Enterprise Value Multiple

Virpax Pharmaceuticals Enterprise Value component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Deferred Long Term Liab
Total Assets		0.97	0.79	-1.0	-0.56	0.49	0.26	0.96	0.02	1.0	0.79	0.97	0.02	0.79	-0.73	-0.21	-0.21
Total Stockholder Equity	0.97		0.63	-0.97	-0.35	0.55	0.06	1.0	-0.09	0.97	0.88	1.0	-0.09	0.88	-0.58	0.03	0.03
Net Tangible Assets	0.79	0.63		-0.78	-0.94	0.24	0.63	0.61	0.16	0.79	0.41	0.63	0.16	0.41	-0.8	-0.68	-0.68
Net Debt	-1.0	-0.97	-0.78		0.55	-0.51	-0.24	-0.97	0.01	-1.0	-0.81	-0.97	0.01	-0.81	0.71	0.18	0.18
Retained Earnings	-0.56	-0.35	-0.94	0.55		-0.15	-0.8	-0.34	-0.24	-0.56	-0.18	-0.35	-0.24	-0.18	0.8	0.78	0.78
Accounts Payable	0.49	0.55	0.24	-0.51	-0.15		0.03	0.56	-0.31	0.49	0.83	0.56	-0.31	0.83	-0.55	0.35	0.35
Total Liab	0.26	0.06	0.63	-0.24	-0.8	0.03		0.05	0.31	0.25	-0.09	0.06	0.31	-0.09	-0.74	-0.58	-0.58
Net Invested Capital	0.96	1.0	0.61	-0.97	-0.34	0.56	0.05		-0.08	0.96	0.89	1.0	-0.08	0.89	-0.58	0.05	0.05
Short Long Term Debt	0.02	-0.09	0.16	0.01	-0.24	-0.31	0.31	-0.08		0.02	-0.14	-0.09	1.0	-0.14	-0.08	-0.33	-0.33
Total Current Assets	1.0	0.97	0.79	-1.0	-0.56	0.49	0.25	0.96	0.02		0.79	0.97	0.02	0.79	-0.72	-0.21	-0.21
Capital Stock	0.79	0.88	0.41	-0.81	-0.18	0.83	-0.09	0.89	-0.14	0.79		0.88	-0.14	1.0	-0.48	0.32	0.32
Net Working Capital	0.97	1.0	0.63	-0.97	-0.35	0.56	0.06	1.0	-0.09	0.97	0.88		-0.09	0.88	-0.58	0.03	0.03
Short Term Debt	0.02	-0.09	0.16	0.01	-0.24	-0.31	0.31	-0.08	1.0	0.02	-0.14	-0.09		-0.14	-0.08	-0.33	-0.33
Common Stock	0.79	0.88	0.41	-0.81	-0.18	0.83	-0.09	0.89	-0.14	0.79	1.0	0.88	-0.14		-0.48	0.32	0.32
Current Deferred Revenue	-0.73	-0.58	-0.8	0.71	0.8	-0.55	-0.74	-0.58	-0.08	-0.72	-0.48	-0.58	-0.08	-0.48		0.45	0.45
Long Term Debt	-0.21	0.03	-0.68	0.18	0.78	0.35	-0.58	0.05	-0.33	-0.21	0.32	0.03	-0.33	0.32	0.45		1.0
Deferred Long Term Liab	-0.21	0.03	-0.68	0.18	0.78	0.35	-0.58	0.05	-0.33	-0.21	0.32	0.03	-0.33	0.32	0.45	1.0

Click cells to compare fundamentals

About Virpax Pharmaceuticals Financial Statements

Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' Enterprise Value, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Enterprise Value Over EBITDA	2.16	2.27
Enterprise Value Multiple	2.16	2.27
Enterprise Value	-5.4 M	-5.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC